Global ANGPTL3-lowering Therapy Market (2025-2033): 30.9% CAGR Fueled by RNAi & Gene-editing Innovations

The global ANGPTL3-lowering therapy market was valued at US$ 99.75 million in 2024 and is projected to reach US$ 1,096.42 million by 2033, growing at a compound annual growth rate (CAGR) of 30.9% during the forecast period 2025-2033.

Market Overview

ANGPTL3-lowering therapies target angiopoietin-like protein 3 (ANGPTL3), a liver-produced protein that regulates lipid metabolism. These therapies, including monoclonal antibodies, antisense oligonucleotides (ASOs), and RNA interference (RNAi) treatments, reduce low-density lipoprotein cholesterol (LDL-C) and triglycerides, addressing unmet needs in patients with hyperlipidemia, homozygous familial hypercholesterolemia (HoFH), and atherosclerotic cardiovascular disease (ASCVD). The market is driven by the rising prevalence of cardiovascular diseases, limitations of traditional therapies like statins, and advancements in novel therapeutic approaches. Key players like Regeneron, Arrowhead Pharmaceuticals, and Verve Therapeutics are leading innovation, with Evkeeza (evinacumab) as the only FDA-approved ANGPTL3 inhibitor for HoFH.

📌 Access valuable insights with our sample report - (Please enter your Corporate Email ID to get priority access):- https://www.datamintelligence.com/download-sample/angptl3-lowering-therapy-market?rk

Market Opportunities

Opportunities include expanding indications for ANGPTL3 inhibitors beyond HoFH, such as heterozygous familial hypercholesterolemia (HeFH) and mixed dyslipidemia, and penetrating emerging markets with growing cardiovascular disease burdens. Advances in RNAi and gene-editing technologies, like Verve Therapeutics' VERVE-201 and VERVE-102, offer potential for long-term lipid management solutions.

Key Trends

Growing adoption of RNAi therapies (e.g., zodasiran) and gene-editing approaches for durable lipid reduction.
Increasing focus on rare lipid disorders like HoFH, supported by orphan drug designations.
Shift toward combination therapies to enhance efficacy in complex lipid disorders.

Recent Developments

May 2024: Arrowhead Pharmaceuticals presented Phase 2 data for zodasiran (ARO-ANG3), showing significant reductions in triglycerides and LDL-C in mixed hyperlipidemia patients.

March 2025: Verve Therapeutics received FDA clearance for VERVE-102, a gene-editing therapy for HeFH, initiating U.S. clinical trials.

January 2024: Ultragenyx announced NICE's recommendation for Evkeeza for HoFH treatment in England, expanding its use for adolescents and adults.

February 2025: Arrowhead Pharmaceuticals planned a Phase III trial for zodasiran in HoFH, following promising Phase IIb ARCHES-2 study results.

Market Dynamics: Drivers

Rising Prevalence of Hyperlipidemia and Cardiovascular Diseases
The global burden of hyperlipidemia and cardiovascular diseases (CVD) is a major driver, with CVD being a leading cause of mortality worldwide, linked to elevated LDL-C and triglycerides. In 2024, approximately 24 million U.S. adults were diagnosed with ASCVD, and 2.6 million had severe hypertriglyceridemia (DelveInsight, 2024). ANGPTL3 inhibitors, such as Evkeeza and zodasiran, offer effective lipid reduction for patients unresponsive to statins or PCSK9 inhibitors, particularly those with HoFH, which affects 1 in 300,000 individuals globally (Ultragenyx, January 2024). Genetic studies confirm that ANGPTL3 loss-of-function mutations lower LDL-C and CVD risk, boosting demand for these therapies.

Market Dynamics: Restraints

Limited Treatment Options
The scarcity of approved ANGPTL3 inhibitors, with only Evkeeza currently FDA-approved, limits market growth. Many HoFH patients rely on multiple lipid-lowering drugs, but variable efficacy due to genetic differences, such as non-functional LDL receptors, reduces treatment options. High costs of biologics like Evkeeza and complex regulatory pathways for new therapies further constrain market expansion.

📌 Speak to Our Senior Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/angptl3-lowering-therapy-market

Market Segment Analysis

By Treatment Type: Monoclonal Antibodies Lead
The monoclonal antibody segment held a 31.6% market share in 2024, driven by Evkeeza (evinacumab), the only FDA-approved ANGPTL3 inhibitor for HoFH. Evkeeza reduces LDL-C by inhibiting ANGPTL3, benefiting patients with rare genetic lipid disorders. Its approval for adults and adolescents (January 2024, NICE recommendation) solidifies its dominance, though emerging RNAi therapies like zodasiran are gaining traction.

By Application
HoFH is the primary application due to its severe lipid profile and limited treatment options. Emerging applications include HeFH and mixed dyslipidemia, with therapies like VERVE-102 targeting broader indications.

By Region
North America dominates, while Asia-Pacific is the fastest-growing region due to increasing cardiovascular disease prevalence and healthcare investments.

📌 Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=angptl3-lowering-therapy-market

Geographical Share

North America Holds Significant Share
North America accounted for a 41.3% market share in 2024, driven by high hyperlipidemia prevalence, advanced healthcare infrastructure, and robust R&D. The U.S. leads with innovations like Verve Therapeutics' VERVE-102, cleared for clinical trials in March 2025 for HeFH. The region's 24 million ASCVD cases and regulatory support for orphan drugs further solidify its dominance.

Asia-Pacific Grows Rapidly
Asia-Pacific held an 18.7% share in 2024, with rapid growth driven by rising hyperlipidemia cases (e.g., 42% of Australian adults have high cholesterol, Heart Foundation, January 2024) and increasing healthcare investments. Countries like China and India are adopting advanced therapies, boosting demand for ANGPTL3 inhibitors.

Major Players
Key companies in the ANGPTL3-lowering therapy market include:

Regeneron Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.
Amgen Inc.
Ionis Pharmaceuticals, Inc. (Akcea Therapeutics)
Silence Therapeutics
Eli Lilly and Company
Novartis AG
Verve Therapeutics, Inc.
CRISPR Therapeutics

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.